Analysts forecast that Nuvectra Corp (NASDAQ:NVTR) will announce earnings of ($0.86) per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Nuvectra’s earnings, with estimates ranging from ($0.91) to ($0.80). Nuvectra reported earnings per share of ($1.09) in the same quarter last year, which suggests a positive year-over-year growth rate of 21.1%. The business is scheduled to announce its next quarterly earnings results on Wednesday, November 7th.

On average, analysts expect that Nuvectra will report full year earnings of ($3.44) per share for the current year, with EPS estimates ranging from ($3.62) to ($3.25). For the next fiscal year, analysts forecast that the company will report earnings of ($2.51) per share, with EPS estimates ranging from ($2.83) to ($2.18). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Nuvectra.

Nuvectra (NASDAQ:NVTR) last posted its quarterly earnings data on Tuesday, August 7th. The company reported ($0.83) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.94) by $0.11. The business had revenue of $13.15 million during the quarter, compared to the consensus estimate of $11.57 million. Nuvectra had a negative return on equity of 77.95% and a negative net margin of 98.28%.

Several research firms have recently weighed in on NVTR. Zacks Investment Research raised Nuvectra from a “sell” rating to a “hold” rating in a report on Friday, June 22nd. BidaskClub cut shares of Nuvectra from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 3rd. Piper Jaffray Companies reiterated a “buy” rating and set a $21.00 price target on shares of Nuvectra in a research note on Wednesday, August 8th. Finally, JMP Securities increased their price objective on Nuvectra from $18.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Wednesday, August 8th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $23.50.

In other news, President Joseph Paul Hanchin sold 1,250 shares of the firm’s stock in a transaction on Monday, August 20th. The shares were sold at an average price of $20.43, for a total value of $25,537.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.60% of the stock is currently owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the company. Engineers Gate Manager LP acquired a new stake in Nuvectra in the second quarter valued at about $437,000. Royal Bank of Canada lifted its position in Nuvectra by 49.8% in the first quarter. Royal Bank of Canada now owns 66,046 shares of the company’s stock valued at $860,000 after purchasing an additional 21,951 shares during the period. Metropolitan Life Insurance Co. NY acquired a new stake in Nuvectra in the second quarter valued at about $105,000. JPMorgan Chase & Co. lifted its holdings in shares of Nuvectra by 1,053.5% in the 1st quarter. JPMorgan Chase & Co. now owns 19,309 shares of the company’s stock valued at $251,000 after buying an additional 17,635 shares during the period. Finally, EAM Investors LLC acquired a new stake in shares of Nuvectra in the 2nd quarter valued at approximately $5,036,000. Institutional investors own 73.95% of the company’s stock.

Shares of NVTR stock traded down $1.23 during trading hours on Friday, hitting $20.79. The stock had a trading volume of 140,157 shares, compared to its average volume of 254,123. The company has a market capitalization of $314.02 million, a P/E ratio of -4.93 and a beta of -1.66. Nuvectra has a twelve month low of $7.60 and a twelve month high of $25.17. The company has a current ratio of 4.10, a quick ratio of 3.77 and a debt-to-equity ratio of 0.75.

Nuvectra Company Profile

Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. It operates through two segments, Nuvectra and NeuroNexus. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs.

See Also: How do investors use RSI to grade stocks?

Get a free copy of the Zacks research report on Nuvectra (NVTR)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Nuvectra (NASDAQ:NVTR)

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with's FREE daily email newsletter.